[Systemic mastocytosis].
HEMATOPOIESIS DISORDER: Systemic mastocytosis is a primary proliferation of mast cells in several noncutaneous tissues. It remains an uncommon disease, difficult to diagnosis and often missed. The spectrum of clinical signs is wide and the course and prognosis are quite variable.


METHODS
Sudden release of mediators by mast cell degranulation lead manifestations of paroxysmal congestion. Pigmentary urticaria is the most frequent cutaneous form. Among visceral localizations, bone involvement is encountered in 90% of the cases, digestive tract and hematological involvement are less frequent. Respiratory and cardiovascular involvement is exceptional.


METHODS
Osteomedullary biopsy is required for diagnosis. Urinary histamine metabolites may be suggestive.


CONCLUSIONS
Prognosis depends on the presence of an associated hematological disorder, found in 30% of the cases.


METHODS
Symptomatic treatment is the rule, aimed at blocking histamine release by mast cell degranulation and avoid the subsequent paroxysmal manifestations.
Duché
A
A
Service de Médecine Interne, CHU Nord, Amiens.
D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D008407:Mast Cells / Q000473:pathology; D008415:Mastocytosis / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy; D011379:Prognosis
D006633:Histamine Antagonists
Les mastocytoses systémiques.